Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 4/20 | 0.69 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.55 |
| ▸ | NPY1R | P25929 | 2/20 | 0.51 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.50 |
| ▸ | HTR2C | P28335 | 2/20 | 0.49 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.48 |
| ▸ | CCR2 | P41597 | 1/20 | 0.48 |
| ▸ | CCR5 | P51681 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | USP5 | P45974 | 1/20 | 0.47 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.47 |
| ▸ | SLC18A3 | Q16572 | 1/20 | 0.46 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8479052 | 0.83 | DRD2 (0.78) | DRD2NPY1RHTR2CSIGMAR1 | |
| SCHEMBL20240320 | 0.83 | DRD2 (0.78) | DRD2NPY1RCHRM4HTR2CSIGMAR1 | |
| SCHEMBL29914653 | 0.82 | DRD2 (1.00) | DRD2HTR2CSIGMAR1 | |
| SCHEMBL21222765 | 0.82 | DRD2 (1.00) | DRD2HTR2CSIGMAR1 | |
| SCHEMBL7200383 | 0.81 | DRD2 (0.66) | DRD2CHRM4HTR2CCCR2CCR5 | |
| SCHEMBL7480157 | 0.81 | DRD2 (0.74) | DRD2NPY1RHTR2C | |
| SCHEMBL14067226 | 0.80 | DRD2 (0.72) | DRD2CHRM4HTR2CCCR2CCR5 | |
| SCHEMBL4949320 | 0.80 | DRD2 (0.64) | DRD2NPY1RCHRM4HTR2CCCR2 | |
| Hydrochloric Acid SCHEMBL30206729 | 0.80 | DRD2 (0.56) | DRD2CHRM4HTR2CCCR2USP5 | |
| SCHEMBL7201323 | 0.80 | DRD2 (0.60) | DRD2NPY1RCHRM4HTR2CCCR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6444675-B2 | PROMOTING WEIGHT LOSS AND TREATING EATING DISORDERS | BRISTOL-MYERS SQUIBB COMPANY | 2002-09-03 | — | — | US | disclosed |
| US-20010049370-A1 | 4-Alkyl and 4-cycloalkyl derivatives of dihydropyridine NPY antagonists | SIT SING-YUEN (US) | 2001-12-06 | — | — | US | disclosed |
| WO-2001085690-A1 | 4-ALKYL AND 4-CYCLOALKYL DERIVATIVES OF DIHYDROPYRIDINE NPY ANTAGONISTS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2001-11-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010049370-A1 | 4-Alkyl and 4-cycloalkyl derivatives of dihydropyridine NPY antagonists | NPY4R, NPY1R, NPY5R | DRD2 164/4885NPSR1 34/4885NPY1R 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.